PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Dans, Antonio Miguel
TI  - Increased Bleeding Risk with Concomitant Use of Antiplatelet Therapy: Dabigatran vs Warfarin
DP  - 2011 Nov 01
TA  - MD Conference Express
PG  - 24--25
VI  - 11
IP  - 10
4099  - http://mdc.sagepub.com/content/11/10/24.short
4100  - http://mdc.sagepub.com/content/11/10/24.full
AB  - The RE-LY trial compared two doses of dabigatran (110 mg BID and 150 mg BID) with open label warfarin (target INR 2 to 3) in 18,113 patients with nonvalvular atrial fibrillation. This post hoc subanalyses from RE-LY, compares the efficacy and safety of dabigatran with warfarin in patients dependent upon use of concomitant antiplatelet therapy.